Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: Eliciting early response signals from phase 1 trials

Oncotarget

Volumn 4, Issue 1, 2013, Pages 156-165

  Subbiah, Ishwaria M ^a   Subbiah, Vivek ^a   Tsimberidou, Apostolia M ^a   Naing, Aung ^a   Kaseb, Ahmed O ^a   Javle, Milind ^a   Fu, Siqing ^a   Hong, David S ^a   Piha Paul, Sarina ^a   Wheler, Jennifer J ^a   Hess, Kenneth R ^a   Janku, Filip ^a   Falchook, Gerald S ^a   Wolff, Robert A ^a   Kurzrock, Razelle ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cholangiocarcinoma; Gallbladder carcinoma; Locoregional therapy; Phase I; Targeted therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CREATININE; ERLOTINIB; FLUOROURACIL; HER 2 INHIBITOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PROTEIN INHIBITOR; RAPAMYCIN; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GALLBLADDER CANCER; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; STABLE DISEASE; SURVIVAL TIME; UPREGULATION;

EID: 84893391899     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.832     Document Type: Article

References (22)

1. Yamaguchi K and Enjoji M. Carcinoma of the gallbladder. A clinicopathology of 103 patients and a newly proposed staging. Cancer. 1988; 62(7):1425-1432.
2. Zhu AX, Hong TS, Hezel AF and Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2011; 15(2):168-181.
3. Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, Wong A, Delclos M, Charnsangavej C and Janjan NA. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002; 53(4):969-974.
4. Hezel AF and Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008; 13(4):415-423.
5. Tyson GL and El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011; 54(1):173-184.
6. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA and McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5(10):1221-1228.
7. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR and Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002; 51 Suppl 6:VI1-9.
8. Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Furuse J, Saito H, Tsuyuguchi T, Yamamoto M, Kayahara M, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008; 15(1):41-54.
9. Anderson CD, Pinson CW, Berlin J and Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004; 9(1):43-57.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M,van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-216.
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-655.
12. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I and Kaye S. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009; 27(16):2692-2696.
13. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13(3):176-181.
14. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M and Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-1281.
15. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore- Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304(16):1812-1820.
16. Macdonald OK and Crane CH. Palliative and postoperative radiotherapy in biliary tract cancer. Surg Oncol Clin N Am. 2002; 11(4):941-954.
17. Bendell JC PK, Jones SF, Barrett E, Guthrie K, Kass CL, Litwiler KS, Napier C and Patnaik A. (2011). A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. AACRNCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. (San Francisco, CA.)
18. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14(12):1351-1356.
19. Xu R.F.Sun JP, Zhang SR, Zhu GS, Li LB, Liao YL, Xie JM and Liao WJ. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother. 2011; 65(1):22-26.
20. Deshpande V,Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX and Hezel AF. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011; www.impactjournals.com/oncotarget 165 Oncotarget 2013; 4: 156-165 11:60.
21. Borger DR,Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, et al. Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist. 2011.
22. Tsimberidou AM IN, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, Wen S, Kurzrock R. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. J Clin Oncol. 2011 29: 2011 (suppl; abstr CRA2500).